Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jimmy Morgan

Emergency Medicine Joplin, MO Doctor of Osteopathy

NPI 1477560712 CMS profile 66815

1717 S Range Line Rd Ste B, Joplin, MO 64804

Open in the dashboard

General payments

$393,528

160 records reported · program years 2019–2025

Research payments

$14,000

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jimmy Morgan of Joplin, MO is reported in the CMS Open Payments database as having received $393,528 across 160 general payments and $14,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,250 23
2024 General $75,200 28
2024 Research $14,000 4
2023 General $40,500 16
2022 General $58,800 24
2021 General $58,100 24
2020 General $54,050 23
2019 General $46,628 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jimmy Morgan
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Jimmy Morgan were reported at $60,250. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Jimmy Morgan Emergency Medicine median Middle half National median
2019 $46,628 $51 $18–$128 $163
2020 $54,050 $29 $16–$99 $114
2021 $58,100 $40 $18–$124 $132
2022 $58,800 $49 $20–$134 $149
2023 $40,500 $51 $22–$142 $160
2024 $75,200 $52 $22–$150 $164
2025 $60,250 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $332,900 134 payments
  2. Shire North American Group Inc $46,600 20 payments
  3. Fresenius Kabi USA, LLC $14,000 4 payments
  4. Amgen Inc. $17 1 payment
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $393,500 158 payments
  2. Food and Beverage $28 2 payments
Products named General payments · program years 2019–2025
  1. Amicus Separator $14,000 4 payments
  2. Repatha $17 1 payment
  3. Prolia $17 1 payment
  4. XIFAXAN $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Fresenius Kabi USA, LLC $14,000 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

455

Median for Family Practice: 1,826

Drug cost

$2,707

Median for Family Practice: $120,094

Branded share of claims

21.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 49 $453
Cephalexin Generic 61 $425
Amoxicillin Generic 101 $372
Methylprednisolone Generic 43 $305
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $275
Doxycycline Hyclate Generic 27 $226
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 18 $206
Azithromycin Generic 54 $205
Ciprofloxacin Hcl Generic 15 $99
Ondansetron Odt Ondansetron Brand 13 $66

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$13,872

Medicare's payments for the services billed

Medicare patients

334

Average age 73

Services billed

373

220 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 31%
Ischemic heart disease 27%
COPD 25%
Depression 25%
Atrial fibrillation 19%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record